Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Актуальные лекарственные взаимодействия: в фокусе – ингибиторы протонной помпы и клопидогрел
Актуальные лекарственные взаимодействия: в фокусе – ингибиторы протонной помпы и клопидогрел
Трухан Д.И. Актуальные лекарственные взаимодействия: в фокусе – ингибиторы протонной помпы и клопидогрел. Consilium Medicum. 2017; 19 (8.1. Гастроэнтерология): 45–48.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Одним из актуальных вопросов рациональной фармакотерапии в современной клинической практике с позиций коморбидности и лекарственной безопасности являются лекарственные взаимодействия. Антиагрегантная терапия представлена большим спектром препаратов, наиболее применяемыми в клинической практике являются ацетилсалициловая кислота и клопидогрел. Для уменьшения рисков формирования желудочно-кишечных осложнений при использовании антитромбоцитарной терапии рекомендован прием ингибиторов протонной помпы. В статье рассмотрены особенности совместного применения клопидогрела и разных ингибиторов протонной помпы, а также результаты метаанализа по этой проблеме лекарственного взаимодействия, опубликованного в 2016 г.
Ключевые слова: лекарственные взаимодействия, клопидогрел, ингибиторы протонной помпы, рабепразол, Разо.
Key words: drug interactions, clopidogrel, proton pump inhibitors, rabeprazole, Razo.
Ключевые слова: лекарственные взаимодействия, клопидогрел, ингибиторы протонной помпы, рабепразол, Разо.
________________________________________________
Key words: drug interactions, clopidogrel, proton pump inhibitors, rabeprazole, Razo.
Полный текст
Список литературы
1. Трухан Д.И., Тарасова Л.В. Лекарственная безопасность и рациональная фармакотерапия в гастроэнтерологической практике. Клин. перспективы гастроэнтерологии, гепатологии. 2013; 5: 9–16. / Trukhan D.I., Tarasova L.V. Lekarstvennaia bezopasnost' i ratsional'naia farmakoterapiia v gastroenterologicheskoi praktike. Klin. perspektivy gastroenterologii, gepatologii. 2013; 5: 9–16. [in Russian]
2. Трухан Д.И. Рациональная фармакотерапия в кардиологии сквозь призму коморбидности и лекарственной безопасности. Справочник поликлинического врача. 2015; 1: 26–31. / Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
3. Бубнова М.Г. Место клопидогреля в лечении больных с атеротромботической болезнью согласно современным рекомендациям. CardioСоматика. 2011; 2 (4): 5–11. / Bubnova M.G. Role of clopidogrel in patients with atherothrombotic disease according to the modern recommendation. Cardiosomatics. 2011; 2 (4): 5–11. [in Russian]
4. Косарев В.В., Бабанов С.А. Клиническая фармакология современных антиагрегантов. CardioСоматика. 2011; 2 (4): 35–40. / Kosarev V.V., Babanov S.A. Clinical pharmacology of current antiaggregants. Cardiosomatics. 2011; 2 (4): 35–40. [in Russian]
5. Попова Л.В., Аксенова М.Б., Хлевчук Т.В. Антиагрегантная терапия в кардиологии. Клин. медицина. 2016; 10: 729–35. / Popova L.V., Aksenova M.B., Khlevchuk T.V. Antiagregantnaia terapiia v kardiologii. Klin. meditsina. 2016; 10: 729–35. [in Russian]
6. Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л. и др. Антиагрегантная терапия у больных с высоким риском развития тромботических осложнений: проблема эффективности, безопасности и приверженности. Клиницист. 2011; 2: 72–9. / Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L. i dr. Antiagregantnaia terapiia u bol'nykh s vysokim riskom razvitiia tromboticheskikh oslozhnenii: problema effektivnosti, bezopasnosti i priverzhennosti. Klinitsist. 2011; 2: 72–9. [in Russian]
7. Явелов И.С. Двойная антитромбоцитарная терапия – проверенный временем эффективный способ лечения острого коронарного синдрома. Consilium Medicum. 2012; 14 (5): 46–54. / Yavelov I.S. Dvoinaia antitrombotsitarnaia terapiia – proverennyi vremenem effektivnyi sposob lecheniia ostrogo koronarnogo sindroma. Consilium Medicum. 2012; 14 (5): 46–54. [in Russian]
8. Типтева Т.А., Затейщиков Д.А. Комбинированная антитромбоцитарная терапия у больных, перенесших обострение ишемической болезни сердца – современные возможности выбора. Consilium Medicum. 2013; 15 (5): 83–6. / Tipteva T.A., Zateishchikov D.A. Kombinirovannaia antitrombotsitarnaia terapiia u bol'nykh, perenesshikh obostrenie ishemicheskoi bolezni serdtsa – sovremennye vozmozhnosti vybora. Consilium Medicum. 2013; 15 (5): 83–6. [in Russian]
9. Маев И.В., Самсонов А.А., Годило-Годлевский В.А. и др. Лекарственное взаимодействие ингибиторов протонной помпы и клопидогреля при их совместном приеме. Клин. медицина. 2013; 5: 15–21. / Maev I.V., Samsonov A.A., Godilo-Godlevskii V.A. i dr. Lekarstvennoe vzaimodeistvie ingibitorov protonnoi pompy i klopidogrelia pri ikh sovmestnom prieme. Klin. meditsina. 2013; 5: 15–21. [in Russian]
10. Корнеева О.Н., Драпкина О.М., Ивашкин В.Т. Нужен ли гастроэнтеролог кардиологическому больному: кому и когда целесообразно назначать ингибиторы протонной помпы. Здравоохранение (Минск). 2014; 1: 50–5. / Korneeva O.N., Drapkina O.M., Ivashkin V.T. Nuzhen li gastroenterolog kardiologicheskomu bol'nomu: komu i kogda tselesoobrazno naznachat' ingibitory protonnoi pompy. Zdravookhranenie (Minsk). 2014; 1: 50–5. [in Russian]
11. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J 2009; 180: 713–8.
12. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34–41.
13. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleveland Clin J Med 2011; 78: 39–49.
14. Лапина Т.Л. Безопасность ингибиторов протонной помпы. Клин. перспективы гастроэнтерологии, гепатологии. 2009; 4: 29–35. / Lapina T.L. Bezopasnost' ingibitorov protonnoi pompy. Klin. perspektivy gastroenterologii, gepatologii. 2009; 4: 29–35. [in Russian]
15. Кляритская И.Л., Максимова Е.В. Лекарственное взаимодействие ингибиторов протонной помпы и клопидогреля. Крымский терапевт. журн. 2009; 2 (13): 38–42. / Kliaritskaia I.L., Maksimova E.V. Lekarstvennoe vzaimodeistvie ingibitorov protonnoi pompy i klopidogrelia. Krymskii terapevt. zhurn. 2009; 2 (13): 38–42. [in Russian]
16. Сеткина С.Б. Клопидогрель и блокаторы протонной помпы: клинически значимое взаимодействие. Лечебное дело. 2012; 1 (23): 17–8. / Setkina S.B. Klopidogrel' i blokatory protonnoi pompy: klinicheski znachimoe vzaimodeistvie. Lechebnoe delo. 2012; 1 (23): 17–8. [in Russian]
17. Ткач С.М., Онищук Л.А. Ингибиторы протонной помпы и риск межлекарственных взаимодействий. Гастроэнтерология. 2015; 2: 91–8. / Tkach S.M., Onishchuk L.A. Ingibitory protonnoi pompy i risk mezhlekarstvennykh vzaimodeistvii. Gastroenterologiia. 2015; 2: 91–8. [in Russian]
18. Hagihara K, Nishiya Y, Kurihara A et al. Comparison of human cytochrome p450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet 2008; 23: 412–20.
19. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology, 11ed. New-York: McGraw-Hill Medical; 2009.
20. Kazui M, Nishiya Y, Ishizuka T et al. Identifi cation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38 (1): 92–9.
21. Fintel Dan J. Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Hlth Risk Manag 2012; 8: 77–89.
22. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale’s pharmacology. London: Elsevier Churchill Livingstone, 2007.
23. Гастроэнтерология. Национальное руководство. М.: ГЭОТАР-Медиа, 2008. / Gastroenterologiia. Natsional'noe rukovodstvo. M.: GEOTAR-Media, 2008. [in Russian]
24. Li XQ, Andersson TB, Ahlstrom M et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Disp 2004; 32: 821–7.
25. Goodman LS, Gilman A, Brunton LL et al. Goodman & Gilman’s the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011.
26. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256–60.
27. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34–41.
28. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleveland Clin J Med 2011; 78: 39–49.
29. Shirai N, Furuta T, Moriyama Y et al. Effects of CYP 2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929–37.
30. Attar M, Lee VH. Pharmacogenomic considerations in drug delivery. Pharmacogenomics 2003; 4: 443–61.
31. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 4: 460–71.
32. Карева Е.Н. Рабепразол через призму «метаболизм-эффективность». РМЖ. 2016; 17: 1172–6. / Kareva E.N. Rabeprazol cherez prizmu «metabolizm-effektivnost'». RMZh. 2016; 17: 1172–6. [in Russian]
33. Sakai T, Aoyama N, Kita T et al. CYP 2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 6: 721–7.
34. Sychev DA, Denisenko NP, Sizova ZM et al. The frequency of CYP 2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med 2015; 8: 111–4.
35. Sugimoto M, Shirai N, Nishino M et al. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP 2C19 genotype in Japanese. Eur J Clin Pharmacol 2014; 9: 1073–8.
36. Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Rev Anti Infect Ther 2005; 3 (6): 863–70.
37. Шульпекова Ю.О. Применение рабепразола в практике гастроэнтеролога. Мед. совет. 2016; 14: 26–31. / Shul'pekova Yu.O. Primenenie rabeprazola v praktike gastroenterologa. Med. sovet. 2016; 14: 26–31. [in Russian]
38. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 12: 913–58.
39. Lin CJ, Yang JC, Uang YS et al. Time dependent amplified pharmacokinetic and pharmacodynamics responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy 2003; 6: 711–9.
40. Andersson T, Hassan-Alin M, Hasselgren G et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 6: 411–26.
41. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002; 9: 595–601.
42. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP 2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 10: 1811–7.
43. Kita T, Sakaeda T, Baba T et al. Different contribution of CYP 2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 2003; 3: 386–90.
44. Niu Q, Wang Z, Zhang Y et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther 2016. pii: 1074248416663647.
45. Liu LP, Wang Y, Si R et al. Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case-control study. Exp Opin Pharmacother 2016; 17 (1): 7–16. DOI: 10.1517/14656566.2016.1110145
46. Zou D, Goh KL. An East Asian Perspective on the Interaction between Proton Pump Inhibitors and Clopidogrel. J Gastroenterol Hepatol 2016. DOI: 10.1111/jgh.13712
47. Furuta T, Sugimoto M, Kodaira C et al. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 2017; 43 (3): 333–42. DOI: 10.1007/s11239-016-1460-2
48. Трухан Д.И. Рациональная фармакотерапия в гастроэнтерологии. Справочник поликлинического врача. 2012; 10: 18–24. / Trukhan D.I. Ratsional'naia farmakoterapiia v gastroenterologii. Handbook for Practitioners Doctors. 2012; 10: 18–24. [in Russian]
49. Трухан Д.И. Выбор лекарственного препарата с позиций рациональной фармакотерапии. Consilium Medicum. 2013; 15 (11): 45–9. / Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 15 (11): 45–9. [in Russian]
50. Дорофеев А.Э., Афанасьев М.В., Рассохина О.А., Сибилев О.В. Некоторые механизмы эзофагопротекции у больных гастроэзофагеальной рефлюксной болезнью и их коррекция. Соврем. гастроэнтерология. 2011; 1: 78–83. / Dorofeev A.E., Afanas'ev M.V., Rassokhina O.A., Sibilev O.V. Nekotorye mekhanizmy ezofagoprotektsii u bol'nykh gastroezofageal'noi refliuksnoi bolezn'iu i ikh korrektsiia. Sovrem. gastroenterologiia. 2011; 1: 78–83. [in Russian]
2. Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
3. Bubnova M.G. Role of clopidogrel in patients with atherothrombotic disease according to the modern recommendation. Cardiosomatics. 2011; 2 (4): 5–11. [in Russian]
4. Kosarev V.V., Babanov S.A. Clinical pharmacology of current antiaggregants. Cardiosomatics. 2011; 2 (4): 35–40. [in Russian]
5. Popova L.V., Aksenova M.B., Khlevchuk T.V. Antiagregantnaia terapiia v kardiologii. Klin. meditsina. 2016; 10: 729–35. [in Russian]
6. Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L. i dr. Antiagregantnaia terapiia u bol'nykh s vysokim riskom razvitiia tromboticheskikh oslozhnenii: problema effektivnosti, bezopasnosti i priverzhennosti. Klinitsist. 2011; 2: 72–9. [in Russian]
7. Yavelov I.S. Dvoinaia antitrombotsitarnaia terapiia – proverennyi vremenem effektivnyi sposob lecheniia ostrogo koronarnogo sindroma. Consilium Medicum. 2012; 14 (5): 46–54. [in Russian]
8. Tipteva T.A., Zateishchikov D.A. Kombinirovannaia antitrombotsitarnaia terapiia u bol'nykh, perenesshikh obostrenie ishemicheskoi bolezni serdtsa – sovremennye vozmozhnosti vybora. Consilium Medicum. 2013; 15 (5): 83–6. [in Russian]
9. Maev I.V., Samsonov A.A., Godilo-Godlevskii V.A. i dr. Lekarstvennoe vzaimodeistvie ingibitorov protonnoi pompy i klopidogrelia pri ikh sovmestnom prieme. Klin. meditsina. 2013; 5: 15–21. [in Russian]
10. Korneeva O.N., Drapkina O.M., Ivashkin V.T. Nuzhen li gastroenterolog kardiologicheskomu bol'nomu: komu i kogda tselesoobrazno naznachat' ingibitory protonnoi pompy. Zdravookhranenie (Minsk). 2014; 1: 50–5. [in Russian]
11. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J 2009; 180: 713–8.
12. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34–41.
13. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleveland Clin J Med 2011; 78: 39–49.
14. Lapina T.L. Bezopasnost' ingibitorov protonnoi pompy. Klin. perspektivy gastroenterologii, gepatologii. 2009; 4: 29–35. [in Russian]
15. Kliaritskaia I.L., Maksimova E.V. Lekarstvennoe vzaimodeistvie ingibitorov protonnoi pompy i klopidogrelia. Krymskii terapevt. zhurn. 2009; 2 (13): 38–42. [in Russian]
16. Setkina S.B. Klopidogrel' i blokatory protonnoi pompy: klinicheski znachimoe vzaimodeistvie. Lechebnoe delo. 2012; 1 (23): 17–8. [in Russian]
17. Tkach S.M., Onishchuk L.A. Ingibitory protonnoi pompy i risk mezhlekarstvennykh vzaimodeistvii. Gastroenterologiia. 2015; 2: 91–8. [in Russian]
18. Hagihara K, Nishiya Y, Kurihara A et al. Comparison of human cytochrome p450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet 2008; 23: 412–20.
19. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology, 11ed. New-York: McGraw-Hill Medical; 2009.
20. Kazui M, Nishiya Y, Ishizuka T et al. Identifi cation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38 (1): 92–9.
21. Fintel Dan J. Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Hlth Risk Manag 2012; 8: 77–89.
22. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale’s pharmacology. London: Elsevier Churchill Livingstone, 2007.
23. Gastroenterologiia. Natsional'noe rukovodstvo. M.: GEOTAR-Media, 2008. [in Russian]
24. Li XQ, Andersson TB, Ahlstrom M et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Disp 2004; 32: 821–7.
25. Goodman LS, Gilman A, Brunton LL et al. Goodman & Gilman’s the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011.
26. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256–60.
27. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34–41.
28. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleveland Clin J Med 2011; 78: 39–49.
29. Shirai N, Furuta T, Moriyama Y et al. Effects of CYP 2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929–37.
30. Attar M, Lee VH. Pharmacogenomic considerations in drug delivery. Pharmacogenomics 2003; 4: 443–61.
31. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 4: 460–71.
32. Kareva E.N. Rabeprazol cherez prizmu «metabolizm-effektivnost'». RMZh. 2016; 17: 1172–6. [in Russian]
33. Sakai T, Aoyama N, Kita T et al. CYP 2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 6: 721–7.
34. Sychev DA, Denisenko NP, Sizova ZM et al. The frequency of CYP 2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med 2015; 8: 111–4.
35. Sugimoto M, Shirai N, Nishino M et al. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP 2C19 genotype in Japanese. Eur J Clin Pharmacol 2014; 9: 1073–8.
36. Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Rev Anti Infect Ther 2005; 3 (6): 863–70.
37. Shul'pekova Yu.O. Primenenie rabeprazola v praktike gastroenterologa. Med. sovet. 2016; 14: 26–31. [in Russian]
38. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 12: 913–58.
39. Lin CJ, Yang JC, Uang YS et al. Time dependent amplified pharmacokinetic and pharmacodynamics responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy 2003; 6: 711–9.
40. Andersson T, Hassan-Alin M, Hasselgren G et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 6: 411–26.
41. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002; 9: 595–601.
42. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP 2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 10: 1811–7.
43. Kita T, Sakaeda T, Baba T et al. Different contribution of CYP 2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 2003; 3: 386–90.
44. Niu Q, Wang Z, Zhang Y et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther 2016. pii: 1074248416663647.
45. Liu LP, Wang Y, Si R et al. Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case-control study. Exp Opin Pharmacother 2016; 17 (1): 7–16. DOI: 10.1517/14656566.2016.1110145
46. Zou D, Goh KL. An East Asian Perspective on the Interaction between Proton Pump Inhibitors and Clopidogrel. J Gastroenterol Hepatol 2016. DOI: 10.1111/jgh.13712
47. Furuta T, Sugimoto M, Kodaira C et al. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 2017; 43 (3): 333–42. DOI: 10.1007/s11239-016-1460-2
48. Trukhan D.I. Ratsional'naia farmakoterapiia v gastroenterologii. Handbook for Practitioners Doctors. 2012; 10: 18–24. [in Russian]
49. Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 15 (11): 45–9. [in Russian]
50. Dorofeev A.E., Afanas'ev M.V., Rassokhina O.A., Sibilev O.V. Nekotorye mekhanizmy ezofagoprotektsii u bol'nykh gastroezofageal'noi refliuksnoi bolezn'iu i ikh korrektsiia. Sovrem. gastroenterologiia. 2011; 1: 78–83. [in Russian]
2. Трухан Д.И. Рациональная фармакотерапия в кардиологии сквозь призму коморбидности и лекарственной безопасности. Справочник поликлинического врача. 2015; 1: 26–31. / Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
3. Бубнова М.Г. Место клопидогреля в лечении больных с атеротромботической болезнью согласно современным рекомендациям. CardioСоматика. 2011; 2 (4): 5–11. / Bubnova M.G. Role of clopidogrel in patients with atherothrombotic disease according to the modern recommendation. Cardiosomatics. 2011; 2 (4): 5–11. [in Russian]
4. Косарев В.В., Бабанов С.А. Клиническая фармакология современных антиагрегантов. CardioСоматика. 2011; 2 (4): 35–40. / Kosarev V.V., Babanov S.A. Clinical pharmacology of current antiaggregants. Cardiosomatics. 2011; 2 (4): 35–40. [in Russian]
5. Попова Л.В., Аксенова М.Б., Хлевчук Т.В. Антиагрегантная терапия в кардиологии. Клин. медицина. 2016; 10: 729–35. / Popova L.V., Aksenova M.B., Khlevchuk T.V. Antiagregantnaia terapiia v kardiologii. Klin. meditsina. 2016; 10: 729–35. [in Russian]
6. Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л. и др. Антиагрегантная терапия у больных с высоким риском развития тромботических осложнений: проблема эффективности, безопасности и приверженности. Клиницист. 2011; 2: 72–9. / Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L. i dr. Antiagregantnaia terapiia u bol'nykh s vysokim riskom razvitiia tromboticheskikh oslozhnenii: problema effektivnosti, bezopasnosti i priverzhennosti. Klinitsist. 2011; 2: 72–9. [in Russian]
7. Явелов И.С. Двойная антитромбоцитарная терапия – проверенный временем эффективный способ лечения острого коронарного синдрома. Consilium Medicum. 2012; 14 (5): 46–54. / Yavelov I.S. Dvoinaia antitrombotsitarnaia terapiia – proverennyi vremenem effektivnyi sposob lecheniia ostrogo koronarnogo sindroma. Consilium Medicum. 2012; 14 (5): 46–54. [in Russian]
8. Типтева Т.А., Затейщиков Д.А. Комбинированная антитромбоцитарная терапия у больных, перенесших обострение ишемической болезни сердца – современные возможности выбора. Consilium Medicum. 2013; 15 (5): 83–6. / Tipteva T.A., Zateishchikov D.A. Kombinirovannaia antitrombotsitarnaia terapiia u bol'nykh, perenesshikh obostrenie ishemicheskoi bolezni serdtsa – sovremennye vozmozhnosti vybora. Consilium Medicum. 2013; 15 (5): 83–6. [in Russian]
9. Маев И.В., Самсонов А.А., Годило-Годлевский В.А. и др. Лекарственное взаимодействие ингибиторов протонной помпы и клопидогреля при их совместном приеме. Клин. медицина. 2013; 5: 15–21. / Maev I.V., Samsonov A.A., Godilo-Godlevskii V.A. i dr. Lekarstvennoe vzaimodeistvie ingibitorov protonnoi pompy i klopidogrelia pri ikh sovmestnom prieme. Klin. meditsina. 2013; 5: 15–21. [in Russian]
10. Корнеева О.Н., Драпкина О.М., Ивашкин В.Т. Нужен ли гастроэнтеролог кардиологическому больному: кому и когда целесообразно назначать ингибиторы протонной помпы. Здравоохранение (Минск). 2014; 1: 50–5. / Korneeva O.N., Drapkina O.M., Ivashkin V.T. Nuzhen li gastroenterolog kardiologicheskomu bol'nomu: komu i kogda tselesoobrazno naznachat' ingibitory protonnoi pompy. Zdravookhranenie (Minsk). 2014; 1: 50–5. [in Russian]
11. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J 2009; 180: 713–8.
12. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34–41.
13. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleveland Clin J Med 2011; 78: 39–49.
14. Лапина Т.Л. Безопасность ингибиторов протонной помпы. Клин. перспективы гастроэнтерологии, гепатологии. 2009; 4: 29–35. / Lapina T.L. Bezopasnost' ingibitorov protonnoi pompy. Klin. perspektivy gastroenterologii, gepatologii. 2009; 4: 29–35. [in Russian]
15. Кляритская И.Л., Максимова Е.В. Лекарственное взаимодействие ингибиторов протонной помпы и клопидогреля. Крымский терапевт. журн. 2009; 2 (13): 38–42. / Kliaritskaia I.L., Maksimova E.V. Lekarstvennoe vzaimodeistvie ingibitorov protonnoi pompy i klopidogrelia. Krymskii terapevt. zhurn. 2009; 2 (13): 38–42. [in Russian]
16. Сеткина С.Б. Клопидогрель и блокаторы протонной помпы: клинически значимое взаимодействие. Лечебное дело. 2012; 1 (23): 17–8. / Setkina S.B. Klopidogrel' i blokatory protonnoi pompy: klinicheski znachimoe vzaimodeistvie. Lechebnoe delo. 2012; 1 (23): 17–8. [in Russian]
17. Ткач С.М., Онищук Л.А. Ингибиторы протонной помпы и риск межлекарственных взаимодействий. Гастроэнтерология. 2015; 2: 91–8. / Tkach S.M., Onishchuk L.A. Ingibitory protonnoi pompy i risk mezhlekarstvennykh vzaimodeistvii. Gastroenterologiia. 2015; 2: 91–8. [in Russian]
18. Hagihara K, Nishiya Y, Kurihara A et al. Comparison of human cytochrome p450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet 2008; 23: 412–20.
19. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology, 11ed. New-York: McGraw-Hill Medical; 2009.
20. Kazui M, Nishiya Y, Ishizuka T et al. Identifi cation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38 (1): 92–9.
21. Fintel Dan J. Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Hlth Risk Manag 2012; 8: 77–89.
22. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale’s pharmacology. London: Elsevier Churchill Livingstone, 2007.
23. Гастроэнтерология. Национальное руководство. М.: ГЭОТАР-Медиа, 2008. / Gastroenterologiia. Natsional'noe rukovodstvo. M.: GEOTAR-Media, 2008. [in Russian]
24. Li XQ, Andersson TB, Ahlstrom M et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Disp 2004; 32: 821–7.
25. Goodman LS, Gilman A, Brunton LL et al. Goodman & Gilman’s the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011.
26. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256–60.
27. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34–41.
28. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleveland Clin J Med 2011; 78: 39–49.
29. Shirai N, Furuta T, Moriyama Y et al. Effects of CYP 2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929–37.
30. Attar M, Lee VH. Pharmacogenomic considerations in drug delivery. Pharmacogenomics 2003; 4: 443–61.
31. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 4: 460–71.
32. Карева Е.Н. Рабепразол через призму «метаболизм-эффективность». РМЖ. 2016; 17: 1172–6. / Kareva E.N. Rabeprazol cherez prizmu «metabolizm-effektivnost'». RMZh. 2016; 17: 1172–6. [in Russian]
33. Sakai T, Aoyama N, Kita T et al. CYP 2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 6: 721–7.
34. Sychev DA, Denisenko NP, Sizova ZM et al. The frequency of CYP 2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med 2015; 8: 111–4.
35. Sugimoto M, Shirai N, Nishino M et al. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP 2C19 genotype in Japanese. Eur J Clin Pharmacol 2014; 9: 1073–8.
36. Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Rev Anti Infect Ther 2005; 3 (6): 863–70.
37. Шульпекова Ю.О. Применение рабепразола в практике гастроэнтеролога. Мед. совет. 2016; 14: 26–31. / Shul'pekova Yu.O. Primenenie rabeprazola v praktike gastroenterologa. Med. sovet. 2016; 14: 26–31. [in Russian]
38. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 12: 913–58.
39. Lin CJ, Yang JC, Uang YS et al. Time dependent amplified pharmacokinetic and pharmacodynamics responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy 2003; 6: 711–9.
40. Andersson T, Hassan-Alin M, Hasselgren G et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 6: 411–26.
41. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002; 9: 595–601.
42. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP 2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 10: 1811–7.
43. Kita T, Sakaeda T, Baba T et al. Different contribution of CYP 2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 2003; 3: 386–90.
44. Niu Q, Wang Z, Zhang Y et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther 2016. pii: 1074248416663647.
45. Liu LP, Wang Y, Si R et al. Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case-control study. Exp Opin Pharmacother 2016; 17 (1): 7–16. DOI: 10.1517/14656566.2016.1110145
46. Zou D, Goh KL. An East Asian Perspective on the Interaction between Proton Pump Inhibitors and Clopidogrel. J Gastroenterol Hepatol 2016. DOI: 10.1111/jgh.13712
47. Furuta T, Sugimoto M, Kodaira C et al. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 2017; 43 (3): 333–42. DOI: 10.1007/s11239-016-1460-2
48. Трухан Д.И. Рациональная фармакотерапия в гастроэнтерологии. Справочник поликлинического врача. 2012; 10: 18–24. / Trukhan D.I. Ratsional'naia farmakoterapiia v gastroenterologii. Handbook for Practitioners Doctors. 2012; 10: 18–24. [in Russian]
49. Трухан Д.И. Выбор лекарственного препарата с позиций рациональной фармакотерапии. Consilium Medicum. 2013; 15 (11): 45–9. / Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 15 (11): 45–9. [in Russian]
50. Дорофеев А.Э., Афанасьев М.В., Рассохина О.А., Сибилев О.В. Некоторые механизмы эзофагопротекции у больных гастроэзофагеальной рефлюксной болезнью и их коррекция. Соврем. гастроэнтерология. 2011; 1: 78–83. / Dorofeev A.E., Afanas'ev M.V., Rassokhina O.A., Sibilev O.V. Nekotorye mekhanizmy ezofagoprotektsii u bol'nykh gastroezofageal'noi refliuksnoi bolezn'iu i ikh korrektsiia. Sovrem. gastroenterologiia. 2011; 1: 78–83. [in Russian]
________________________________________________
2. Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
3. Bubnova M.G. Role of clopidogrel in patients with atherothrombotic disease according to the modern recommendation. Cardiosomatics. 2011; 2 (4): 5–11. [in Russian]
4. Kosarev V.V., Babanov S.A. Clinical pharmacology of current antiaggregants. Cardiosomatics. 2011; 2 (4): 35–40. [in Russian]
5. Popova L.V., Aksenova M.B., Khlevchuk T.V. Antiagregantnaia terapiia v kardiologii. Klin. meditsina. 2016; 10: 729–35. [in Russian]
6. Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L. i dr. Antiagregantnaia terapiia u bol'nykh s vysokim riskom razvitiia tromboticheskikh oslozhnenii: problema effektivnosti, bezopasnosti i priverzhennosti. Klinitsist. 2011; 2: 72–9. [in Russian]
7. Yavelov I.S. Dvoinaia antitrombotsitarnaia terapiia – proverennyi vremenem effektivnyi sposob lecheniia ostrogo koronarnogo sindroma. Consilium Medicum. 2012; 14 (5): 46–54. [in Russian]
8. Tipteva T.A., Zateishchikov D.A. Kombinirovannaia antitrombotsitarnaia terapiia u bol'nykh, perenesshikh obostrenie ishemicheskoi bolezni serdtsa – sovremennye vozmozhnosti vybora. Consilium Medicum. 2013; 15 (5): 83–6. [in Russian]
9. Maev I.V., Samsonov A.A., Godilo-Godlevskii V.A. i dr. Lekarstvennoe vzaimodeistvie ingibitorov protonnoi pompy i klopidogrelia pri ikh sovmestnom prieme. Klin. meditsina. 2013; 5: 15–21. [in Russian]
10. Korneeva O.N., Drapkina O.M., Ivashkin V.T. Nuzhen li gastroenterolog kardiologicheskomu bol'nomu: komu i kogda tselesoobrazno naznachat' ingibitory protonnoi pompy. Zdravookhranenie (Minsk). 2014; 1: 50–5. [in Russian]
11. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J 2009; 180: 713–8.
12. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34–41.
13. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleveland Clin J Med 2011; 78: 39–49.
14. Lapina T.L. Bezopasnost' ingibitorov protonnoi pompy. Klin. perspektivy gastroenterologii, gepatologii. 2009; 4: 29–35. [in Russian]
15. Kliaritskaia I.L., Maksimova E.V. Lekarstvennoe vzaimodeistvie ingibitorov protonnoi pompy i klopidogrelia. Krymskii terapevt. zhurn. 2009; 2 (13): 38–42. [in Russian]
16. Setkina S.B. Klopidogrel' i blokatory protonnoi pompy: klinicheski znachimoe vzaimodeistvie. Lechebnoe delo. 2012; 1 (23): 17–8. [in Russian]
17. Tkach S.M., Onishchuk L.A. Ingibitory protonnoi pompy i risk mezhlekarstvennykh vzaimodeistvii. Gastroenterologiia. 2015; 2: 91–8. [in Russian]
18. Hagihara K, Nishiya Y, Kurihara A et al. Comparison of human cytochrome p450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet 2008; 23: 412–20.
19. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology, 11ed. New-York: McGraw-Hill Medical; 2009.
20. Kazui M, Nishiya Y, Ishizuka T et al. Identifi cation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38 (1): 92–9.
21. Fintel Dan J. Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Hlth Risk Manag 2012; 8: 77–89.
22. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale’s pharmacology. London: Elsevier Churchill Livingstone, 2007.
23. Gastroenterologiia. Natsional'noe rukovodstvo. M.: GEOTAR-Media, 2008. [in Russian]
24. Li XQ, Andersson TB, Ahlstrom M et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Disp 2004; 32: 821–7.
25. Goodman LS, Gilman A, Brunton LL et al. Goodman & Gilman’s the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011.
26. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256–60.
27. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34–41.
28. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleveland Clin J Med 2011; 78: 39–49.
29. Shirai N, Furuta T, Moriyama Y et al. Effects of CYP 2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929–37.
30. Attar M, Lee VH. Pharmacogenomic considerations in drug delivery. Pharmacogenomics 2003; 4: 443–61.
31. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 4: 460–71.
32. Kareva E.N. Rabeprazol cherez prizmu «metabolizm-effektivnost'». RMZh. 2016; 17: 1172–6. [in Russian]
33. Sakai T, Aoyama N, Kita T et al. CYP 2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 6: 721–7.
34. Sychev DA, Denisenko NP, Sizova ZM et al. The frequency of CYP 2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med 2015; 8: 111–4.
35. Sugimoto M, Shirai N, Nishino M et al. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP 2C19 genotype in Japanese. Eur J Clin Pharmacol 2014; 9: 1073–8.
36. Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Rev Anti Infect Ther 2005; 3 (6): 863–70.
37. Shul'pekova Yu.O. Primenenie rabeprazola v praktike gastroenterologa. Med. sovet. 2016; 14: 26–31. [in Russian]
38. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 12: 913–58.
39. Lin CJ, Yang JC, Uang YS et al. Time dependent amplified pharmacokinetic and pharmacodynamics responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy 2003; 6: 711–9.
40. Andersson T, Hassan-Alin M, Hasselgren G et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 6: 411–26.
41. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002; 9: 595–601.
42. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP 2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 10: 1811–7.
43. Kita T, Sakaeda T, Baba T et al. Different contribution of CYP 2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 2003; 3: 386–90.
44. Niu Q, Wang Z, Zhang Y et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther 2016. pii: 1074248416663647.
45. Liu LP, Wang Y, Si R et al. Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case-control study. Exp Opin Pharmacother 2016; 17 (1): 7–16. DOI: 10.1517/14656566.2016.1110145
46. Zou D, Goh KL. An East Asian Perspective on the Interaction between Proton Pump Inhibitors and Clopidogrel. J Gastroenterol Hepatol 2016. DOI: 10.1111/jgh.13712
47. Furuta T, Sugimoto M, Kodaira C et al. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 2017; 43 (3): 333–42. DOI: 10.1007/s11239-016-1460-2
48. Trukhan D.I. Ratsional'naia farmakoterapiia v gastroenterologii. Handbook for Practitioners Doctors. 2012; 10: 18–24. [in Russian]
49. Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 15 (11): 45–9. [in Russian]
50. Dorofeev A.E., Afanas'ev M.V., Rassokhina O.A., Sibilev O.V. Nekotorye mekhanizmy ezofagoprotektsii u bol'nykh gastroezofageal'noi refliuksnoi bolezn'iu i ikh korrektsiia. Sovrem. gastroenterologiia. 2011; 1: 78–83. [in Russian]
Авторы
Д.И.Трухан*
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12
*dmitry_trukhan@mail.ru
Omsk State Medical University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, d. 12
*dmitry_trukhan@mail.ru
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12
*dmitry_trukhan@mail.ru
________________________________________________
Omsk State Medical University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, d. 12
*dmitry_trukhan@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.